DDInter130 DDInter581
Atenolol is a cardioselective beta-blocker used in a variety of cardiovascular conditions. Sir James Black, a Scottish pharmacologist, pioneered the use of beta-blockers for the management of angina pectoris in 1958 for which he received the Nobel Prize. Beta-blockers quickly became popular in clinical use and where subsequently investigated for use in myocardial infarction, arrhythmias, and hypertension during the 1960s. Later they continued to be investigated for use in heart failure throughout the 1970-1980s. Atenolol itself was developed early on in this history by Alvogen Malta under the trade name Tenormin and received FDA approval in September, 1981.[label] Despite being one of the most widely prescribed beta blockers, evidence suggests atenolol may not significantly reduce mortality, and only modestly reduce the risk of cardiovascular disease in patients with hypertension.[A235850,A235855] A Cochrane review
Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Atenolol {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is upregulated by {v} (Compound) Dolasetron
Atenolol {u} (Compound) causes {v} (Side Effect) Ataxia
Ataxia {u} (Side Effect) is caused by {v} (Compound) Dolasetron
Atenolol {u} (Compound) resembles {v} (Compound) Pindolol
Pindolol {u} may lead to a major life threatening interaction when taken with {v} Dolasetron
Atenolol {u} (Compound) resembles {v} (Compound) Bisoprolol
Bisoprolol {u} may lead to a major life threatening interaction when taken with {v} Dolasetron
Atenolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} may lead to a major life threatening interaction when taken with {v} Dolasetron
Atenolol {u} (Compound) resembles {v} (Compound) Metoprolol
Metoprolol {u} may lead to a major life threatening interaction when taken with {v} Dolasetron
Atenolol {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is regulated by {v} (Gene) MCOLN1
MCOLN1 {u} (Gene) is upregulated by {v} (Compound) Dolasetron
Atenolol {u} (Compound) causes {v} (Side Effect) Ataxia
Ataxia {u} (Side Effect) is caused by {v} (Compound) Hyoscyamine
Hyoscyamine {u} (Compound) resembles {v} (Compound) Dolasetron
Atenolol {u} (Compound) causes {v} (Side Effect) Paraesthesia
Paraesthesia {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolasetron
Atenolol {u} (Compound) causes {v} (Side Effect) Aspartate aminotransferase increased
Aspartate aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Rifabutin
Rifabutin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolasetron
Atenolol (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Dolasetron (Compound)
Atenolol (Compound) causes Ataxia (Side Effect) and Ataxia (Side Effect) is caused by Dolasetron (Compound)
Atenolol (Compound) resembles Pindolol (Compound) and Pindolol may lead to a major life threatening interaction when taken with Dolasetron
Atenolol (Compound) resembles Bisoprolol (Compound) and Bisoprolol may lead to a major life threatening interaction when taken with Dolasetron
Atenolol (Compound) resembles Acebutolol (Compound) and Acebutolol may lead to a major life threatening interaction when taken with Dolasetron
Atenolol (Compound) resembles Metoprolol (Compound) and Metoprolol may lead to a major life threatening interaction when taken with Dolasetron
Atenolol (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is regulated by MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Dolasetron (Compound)
Atenolol (Compound) causes Ataxia (Side Effect) and Ataxia (Side Effect) is caused by Hyoscyamine (Compound) and Hyoscyamine (Compound) resembles Dolasetron (Compound)
Atenolol (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Dolasetron
Atenolol (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Rifabutin (Compound) and Rifabutin may cause a minor interaction that can limit clinical effects when taken with Dolasetron